OssDsign AB (publ) (STO:OSSD)
Sweden · Delayed Price · Currency is SEK | Market Cap | 457.99M -64.2% |
| Revenue (ttm) | 172.55M +14.0% |
| Net Income | -47.88M |
| EPS | -0.49 |
| Shares Out | 110.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,169 |
| Open | 4.145 |
| Previous Close | 4.115 |
| Day's Range | 4.090 - 4.230 |
| 52-Week Range | 3.335 - 16.720 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | 6.40 (+54.59%) |
| Earnings Date | Aug 18, 2026 |
About OssDsign AB
OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in the United States. The company offers OssDsign Catalyst, a nanosynthetic bone graft engages in dual bone formation pathways through fusion mass. OssDsign AB (publ) was founded in 2011 and is headquartered in Uppsala, Sweden. [Read more]
Financial Performance
In 2025, OssDsign AB's revenue was 180.16 million, an increase of 34.51% compared to the previous year's 133.94 million. Losses were -50.99 million, 2.68% more than in 2024.
Financial StatementsNews
OssDsign AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3.6% revenue decline in USD, mainly due to currency effects and operational slowdowns. Leadership changes, sales force expansion, and new product launches are expected to drive improved momentum in H2 2026.
OssDsign AB Quarterly report: Q1 2026
OssDsign AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
OssDsign AB Earnings Call Transcript: Q4 2025
Q4 saw 24% constant currency growth and a 96.3% gross margin, with full year sales up 45% to SEK 180.2 million. Strategic focus is on U.S. expansion, new product launches, and achieving SEK 400 million sales by 2028.
OssDsign AB Quarterly report: Q4 2025
OssDsign AB has published its Q4 2025 quarterly earnings report on February 3, 2026.
OssDsign AB Annual report: Q4 2025
OssDsign AB has published its Q4 2025 annual report on February 3, 2026.
OssDsign AB Transcript: ABGSC Investor Days
The company is focused on property investment, with a strong European presence and a strategy to grow recurring revenues through co-investments and scalable products. Recent restructuring aims to clarify earnings and strengthen core markets, while maintaining a solid cash position.
OssDsign AB Earnings Call Transcript: Q3 2025
Strong organic growth and record EBIT were achieved despite seasonality and currency headwinds, with robust gross margins and continued expansion in the US market. Execution of the new growth strategy is underway, supported by a strengthened balance sheet and upcoming product launches.
OssDsign AB Quarterly report: Q3 2025
OssDsign AB has published its Q3 2025 quarterly earnings report on November 4, 2025.
OssDsign AB Earnings Call Transcript: Q2 2025
Organic growth reached 73% year-over-year, with gross margin at 96.8% and LTM revenue up 68%. Over SEK 160 million was raised to fund the Scale to Profit strategy, targeting SEK 400 million in sales by 2028 and major U.S. market expansion.
OssDsign AB Quarterly report: Q2 2025
OssDsign AB has published its Q2 2025 quarterly earnings report on August 19, 2025.
OssDsign AB Transcript: Study Update
A real-world registry study of 108 complex spinal fusion patients achieved an 88.4% fusion rate at 12 months, with high success across all high-risk groups and significant improvements in pain and quality of life. These results exceed expectations and support broader clinical adoption.
OssDsign AB Press release: Study Update
OssDsign AB issued a press release on June 30, 2025, disclosing material business information to investors.